Literature DB >> 16260781

Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4.

Wei Liu1, Shunqing Wang, Shi Wei, Li Sun, Xu Feng.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL) plays a crucial role in osteoclast differentiation, function, and survival. RANKL exerts its effect by activating its receptor RANK (receptor activator of NF-kappaB), which recruits various intracellular signaling molecules via specific motifs in its cytoplasmic tail. Previously, we identified three RANK cytoplasmic motifs (Motif 1, 369PFQEP373; Motif 2, 559PVQEET564; and Motif 3, 604PVQEQG609) mediating osteoclast formation and function. Here, we investigated RANK cytoplasmic motifs involved in osteoclast survival. Motif 1, in contrast to its minimal role in osteoclast formation and function, plays a predominant role in promoting osteoclast survival. Moreover, whereas Motif 2 and Motif 3 are highly potent in osteoclast formation and function, they exert a moderate effect on osteoclast survival. We also investigated the role of these motifs in activating Akt/protein kinase B (PKB), which has been implicated in RANKL-induced osteoclast survival. Motif 1, but not Motif 2 or Motif 3, is able to stimulate Akt/PKB activation. Because Akt/PKB has been shown to utilize distinct downstream effectors (glycogen synthase kinase-3beta, FKHR/FOXO1a, BAD, and AFX/FOXO4) to regulate cell survival, we next determined which downstream effector(s) is activated by Akt/PKB to promote osteoclast survival. Our data revealed that RANKL only stimulates AFX/FOXO4 phosphorylation, indicating that AFX/FOXO4 is a key downstream target activated by Akt/PKB to modulate osteoclast survival. Taken together, we conclude that Motif 1 plays a predominant role in mediating osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260781     DOI: 10.1074/jbc.M509006200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Quantitative trait locus on chromosome X affects bone loss after maturation in mice.

Authors:  Shuzo Okudaira; Motoyuki Shimizu; Bungo Otsuki; Rika Nakanishi; Akira Ohta; Keiichi Higuchi; Masanori Hosokawa; Tadao Tsuboyama; Takashi Nakamura
Journal:  J Bone Miner Metab       Date:  2010-03-31       Impact factor: 2.626

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

4.  Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: a novel mechanism mediating its blockade of osteoclastogenesis.

Authors:  Jing Cheng; Jianzhong Liu; Zhenqi Shi; Duorong Xu; Shaokai Luo; Gene P Siegal; Xu Feng; Shi Wei
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

5.  Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.

Authors:  Yuyu Li; Zhenqi Shi; Joel Jules; Shenyuan Chen; Robert A Kesterson; Dongfeng Zhao; Ping Zhang; Xu Feng
Journal:  J Bone Miner Res       Date:  2019-08-02       Impact factor: 6.741

Review 6.  Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis.

Authors:  Joel Jules; Jason W Ashley; Xu Feng
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

Review 7.  Sirtuins and FoxOs in osteoporosis and osteoarthritis.

Authors:  Maria Almeida; Ryan M Porter
Journal:  Bone       Date:  2019-02-06       Impact factor: 4.398

8.  Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.

Authors:  Joel Jules; Ping Zhang; Jason W Ashley; Shi Wei; Zhenqi Shi; Jianzhong Liu; Suzanne M Michalek; Xu Feng
Journal:  J Biol Chem       Date:  2012-03-13       Impact factor: 5.157

9.  A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone.

Authors:  Hong Chen; Linda C Gilbert; X Lu; Zhaofan Liu; Shaojin You; M Neale Weitzmann; Mark S Nanes; John Adams
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

10.  CCAAT/Enhancer-binding Protein α (C/EBPα) Is Important for Osteoclast Differentiation and Activity.

Authors:  Joel Jules; Wei Chen; Xu Feng; Yi-Ping Li
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.